Clinical trial
A United States Study of the Safety and Tolerability of Corlux for Psychotic…
NCT00128479 · Corcept Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00128479 |
|---|---|
| Title | A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic… |
| Lead sponsor | Corcept Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg |
| Enrollment | 443 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Aug 10, 2005 |
| Last update posted | Feb 15, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: